Ali, Sapya S.

HRN: 10-74-98  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/13/2026
CLINDAMYCIN 150MG/ML, 4ML (AMP)
03/13/2026
03/19/2026
IV
600 MG
Q8
CELLULITIS
Checking Initial Appropriateness 
03/13/2026
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
03/13/2026
03/20/2026
IV
1.5g
Q6
Furuncle
Checking Initial Appropriateness 
03/23/2026
CLINDAMYCIN 150MG/ML, 4ML (AMP)
03/23/2026
03/30/2026
IV
600mg
Q8
Infected Wound 600mg IV (4ml) 1 Amp X 3doses Per Day X 7 Days = 21 Amps/quantity
Remove - Pending Acceptance
03/23/2026
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
03/23/2026
03/30/2026
IV
1.5
Q6
Cellulitis
Checking Initial Appropriateness 
03/24/2026
CLINDAMYCIN 150MG/ML, 4ML (AMP)
03/24/2026
03/31/2026
IV
600 MG
Q6
CELLULITIS
Checking Initial Appropriateness 
03/28/2026
CLINDAMYCIN 300MG (CAP)
03/28/2026
04/03/2026
PO
300mg
Q8
Cellulits
Remove - Pending Acceptance

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: